Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
134 Results for "
GLUTs
" in MedChemExpress (MCE) Product Catalog:
Products (134)
134 Results for "GLUTs" in MCE Product Catalog:
Cat. No.: HY-D3410
CAS No.: 2991899-29-5
Cat. No.: HY-D3311
Category:
Target:
Cat. No.: HY-129165
CAS No.: 618361-63-0
Target:
Research Areas:
ZINC08383544 is a PKM2 activator with anti-tumor activity. ZINC08383544 binds to the dimer-dimer interface of PKM2, promotes tetramer formation, blocks nuclear translocation, inhibits the expression of glycolysis-related genes such as GLUT1, and reduces T cell-mediated inflammatory responses. ZINC08383544 can be used in cancer-related research such as cervical cancer .
Cat. No.: HY-13753R
CAS No.: 18883-66-4
Synonyms: Streptozocin (Standard); NSC-85998 (Standard); U 9889 (Standard)
Cat. No.: HY-137677
CAS No.: 37589-80-3
Synonyms: Guanosine 5'-[γ-thio]triphosphate
Target:
Research Areas:
GTPγS (Guanosine 5'-[γ-thio]triphosphate) is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS to couple with G- protein α, to study its effect on kinase activity. GTPγS acts as a component of lysis buffer .
Cat. No.: HY-184703
Research Areas:
Antidiabetic agent 9 is an orally active antidiabetic agent. Antidiabetic agent 9 promotes the translocation of GLUT4 to the cell surface, activates the AMPK signaling pathway, and has no effect on the PI-3-K/AKT signaling pathway. Antidiabetic agent 9 reduces blood glucose levels in Streptozotocin (HY-13753)-induced diabetic rats. Antidiabetic agent 9 can be used in the research of diabetes .
Cat. No.: HY-182250
CAS No.: 2505339-87-5
Research Areas:
BR103354 is an orally active, selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 14 nM against hFAP. BR103354 restores the levels of phosphorylated ERK and Glut1 that are reduced by co-treatment with hFGF21 and FAP, decreases non-fasting blood glucose concentrations, improves glucose tolerance, and reduces hepatic triglyceride content. BR103354 ameliorates hepatic steatosis and hepatic fibrosis. BR103354 can be used in the research of type 2 diabetes and non-alcoholic steatohepatitis .
Cat. No.: HY-180784
Target:
Research Areas:
Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes .
Cat. No.: HY-182000
CAS No.: 3055112-52-9
Research Areas:
Xanthine oxidase-IN-23 (Compound BPF) is an orally active, reversible, mixed-type Xanthine oxidase inhibitor with an IC50 of 3.33 μM. Xanthine oxidase-IN-23 directly binds to XOD in a reversible mixed-type manner to inhibit its catalytic activity. Xanthine oxidase-IN-23 upregulates ABCG2 and downregulates GLUT9 to promote renal urate excretion. Xanthine oxidase-IN-23 reduces serum urate levels and improves renal function in hyperuricemic mice. Xanthine oxidase-IN-23 can be used in the research of hyperuricemia .
Category:
Infection Ketones, Aldehydes, Acids Phenols Polyphenols Plants Other Families Extract Disease Research Fields
Target:
Cat. No.: HY-W010736R
CAS No.: 30334-71-5
Category:
Target:
Cat. No.: HY-123986R
CAS No.: 68003-38-3
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
CTPI-2 (Standard) is the analytical standard of CTPI-2 (HY-123986). This product is intended for research and analytical applications. CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .
Cat. No.: HY-128447R
CAS No.: 10152-76-8
Cat. No.: HY-142444
CAS No.: 2647975-06-0
Target:
Research Areas:
SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelial cells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelial cells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3) .
Cat. No.: HY-N0755R
CAS No.: 17306-46-6
Cat. No.: HY-177903
CAS No.: 2003231-25-0
Target:
Research Areas:
Triptolide-6-succinate-β-D-glucose (Compound 2) is a glucose-conjugated derivative of Triptolide (HY-32735). Triptolide-6-succinate-β-D-glucose is a tumor-selective prodrug targeting glucose transporters ( GLUT). Triptolide-6-succinate-β-D-glucose can induce the degradation of the RPB subunit of RNA polymerase II. Triptolide-6-succinate-β-D-glucose inhibits the proliferation of HEK293T cells with an IC50 value of 268 nM. Triptolide-6-succinate-β-D-glucose can be used for the research of cancer, such as prostatic cancer .
Cat. No.: HY-178447
Research Areas:
PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .
Cat. No.: HY-175767
Target:
Research Areas:
PROTAC BRD4 Degrader-39 is a selective targeting Bromodomain protein 4 (BRD4) degrader with an DC50 value of 24.66 nM. PROTAC BRD4 Degrader-39 conjugates BRD PROTAC (ARV-771) (HY-100972) with carbohydrate. PROTAC BRD4 Degrader-39 selectively delivers to tumor cells with high GLUT1 expression, followed by GSH-triggered release of ARV-771 and degrades BRD4. PROTAC BRD4 Degrader-39 can inhibit tumor growth and show no significant toxicity. PROTAC BRD4 Degrader-39 can be used for the research of cancer, such as breast cancer .
Cat. No.: HY-W747548
CAS No.: 116180-17-7
Target:
Drug Derivative p38 MAPK GSK-3 ERK DNA/RNA Synthesis PI3K mTOR Akt GLUT
Research Areas:
12 (S)-HEPE is an oxidation product of Eicosapentaenoic acid (HY-B0660) . 12 (S)-HEPE activates p38α, GSKβ, CREB, and ERK1/2. 12 (S)-HEPE induces DNA synthesis. 12 (S)-HEPE leads to activation of the PI3K-mTORC2-Akt signaling pathway and translocation of Glut4 to the plasma membrane. 12 (S)-HEPE increases glucose uptake. 12 (S)-HEPE reduces body weight gain in HFD mice. 12 (S)-HEPE can be used in research on colorectal cancer, zymosan-induced peritonitis, diabetes, and obesity .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
